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the small molecule inhibitor 
anle145c thermodynamically traps 
human islet amyloid peptide in the 
form of non-cytotoxic oligomers
Manikam S. Saravanan1, Sergey Ryazanov2,3,4, Andrei Leonov2,3,4, Janine nicolai5, 
patrique praest6, Armin Giese7, Roland Winter5, Lucie Khemtemourian8,9*, 
christian Griesinger2,3,4* & J. Antoinette Killian1*
Type 2 diabetes (T2DM) is associated with aggregation of the human islet amyloid polypeptide (hIAPP) 
into cytotoxic amyloid species. Here we tested the effect of a diphenylpyrazole (DPP)-derived small 
molecule inhibitor, anle145c, on cytotoxicity and on aggregation properties of hIAPP. We demonstrate 
that incubation of hIAPP with the inhibitor yields ~10 nm-sized non-toxic oligomers, independent 
of the initial aggregation state of hIAPP. This suggests that anle145c has a special mode of action in 
which anle145c-stabilized oligomers act as a thermodynamic sink for the preferred aggregation state 
of hIAPP and anle145c. We also demonstrate that the inhibitor acts in a very efficient manner, with sub-
stoichiometric concentrations of anle145c being sufficient to (i) inhibit hIAPP-induced death of INS-1E 
cells, (ii) prevent hIAPP fibril formation in solution, and (iii) convert preformed hIAPP fibrils into non-
toxic oligomers. Together, these results indicate that anle145c is a promising candidate for inhibition of 
amyloid formation in T2DM.
Misfolding of proteins and aggregation into amyloid structures is associated with a number of diseases, including 
type 2 diabetes (T2DM), Parkinson’s disease and Alzheimer’s disease1–4. These so-called amyloid diseases in gen-
eral have the hallmark of an age-related pathological effect. However, T2DM stands apart in that it is a common 
metabolic disease, linked to life style and obesity5–7, that increasingly affects people even at an early age7–9. Its 
prevalence around the world is beginning to take on epidemic proportions and T2DM thereby represents a major 
health problem in society7,10.
A prominent pathological event in T2DM is believed to be the formation of toxic amyloid species by a 37 
amino acid protein known as human islet amyloid polypeptide (hIAPP)11–13. hIAPP is a hormone that is 
co-secreted with insulin in the β-cells in the islets of Langerhans in the pancreas. Under pathological condi-
tions typical for T2DM, hIAPP is produced at relatively high concentrations, thereby promoting aggregation and 
contributing to pancreatic cell death14,15. The aggregation process furthermore can be affected by factors such as 
the presence of metal ions, insulin, sulfated glycans and membranes16–25, thereby complicating interpretation of 
in vivo studies on a molecular level. Nevertheless, an important role for hIAPP in T2DM is underscored by the 
observations that a high prevalence of hIAPP aggregates is found in humans with T2DM5,11,26 and that for species 
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whose IAPP cannot form fibrils it has been reported that they do not develop T2DM characterized by islet amy-
loid deposits27–29.
Inhibition of hIAPP amyloid formation is considered to be an effective strategy to help combat T2DM. Several 
natural small molecule amyloid inhibitor compounds, such as epigallocatechin gallate (EGCG), resveratrol and 
curcumin, as well as a variety of synthetic inhibitors have been shown to be able to inhibit hIAPP fibrillation or to 
reduce the cytotoxic activity of hIAPP4,30–39. However, most of these inhibitors were found to act efficiently only 
at relatively high concentrations.
Recently, a family of di-phenyl pyrazole (DPP) amyloid inhibitors has been developed that act as promising 
oligomer modulators to combat amyloid diseases40. Notably, the lead compound “anle138b” was found to inhibit 
protein aggregation in case of prion disease, Parkinson’s disease (PD), Alzheimer’s disease (AD), Multiple System 
Atrophy (MSA) and Creutzfeldt-Jakob disease (CJD) in vitro and in vivo40–47. For none of the DPP compounds, 
the effect on hIAPP has been tested. Yet hIAPP is an interesting target, because it forms oligomers that have some 
features that are different from those of other well-studied amyloid forming proteins48.
Here we set out to elucidate whether DPP compounds can be effective against aggregation of hIAPP. For this 
initial study, we selected the DPP-derived small-molecule inhibitor anle145c because it structurally resembles the 
very lipophilic lead compound anle138b and is likewise an efficient inhibitor of amyloid aggregation. Anle145c 
also has the advantage of being more water soluble than anle138b with a solubility between ~50 to 100 µM com-
pared to ~0.2 µM for anle138b40. Therefore, artefacts due to aggregation of the inhibitor in the aqueous envi-
ronment are avoided and the interaction of anle145c with hIAPP can easily and systematically be studied at 
concentrations that would not be feasible for anle138b.
Our findings indicate that the molecule efficiently inhibits both aggregation and cytotoxicity by hIAPP 
at sub-stoichiometric concentrations and in addition is able to convert mature amyloid fibrils into non-toxic 
anle145c-stabilized oligomers by stabilizing non-toxic oligomers thermodynamically. The results suggest that 
anle145c is a promising candidate to inhibit protein aggregation in case of T2DM.
Results
hIAPP and anle145c. In this study we investigated the interaction between hIAPP and the small-molecule 
inhibitor anle145c. Figure 1 shows the structures of these molecules.
Anle145c protects cells from hIAPP-induced toxicity. The ability of anle145c to protect living cells 
from hIAPP-induced cytotoxicity was tested using insulinoma (INS-1E) cells from a rat pancreatic beta cell line. 
These cells closely resemble the insulin-producing beta-cells in the pancreas that are known to become damaged 
under conditions of T2DM15, most likely as a consequence of hIAPP aggregation.
As shown by the micrograph in Fig. 2A, untreated INS-1E cells show a normal phenotype for adherent cells. 
Most of the cells are viable and attached to the cell culture dish. By contrast, the hIAPP-treated cells seem to have 
an impaired cell growth. Upon incubation with hIAPP a change in cell-morphology is observed and most of the 
cells are detached, indicating a considerable amount of cell-death (Fig. 2B). However, when a low concentration 
of anle145c is added prior to hIAPP, the cells again grow with a morphology similar as when no hIAPP is present 
(Fig. 2C). Flow cytometry based DAPI staining (Fig. 2G) confirms hIAPP-induced cell death and demonstrates 
that the inhibitor can rescue cell viability. A concentration of 1 µM anle145c, corresponding to a 1/10 molar ratio 
of inhibitor to hIAPP already is sufficient to yield a maximum rescue, while further increasing the anle145c con-
centration does not cause further inhibition of hIAPP-induced cell death. In addition, the results indicate that 
the concentration of DMSO, present in all samples containing either anle145c or hIAPP or both, does not cause 
substantial cell death and that also the inhibitor itself is not cytotoxic.
As an independent control model, we used cells from a human melanoma cell line (MJS cells), for which 
hIAPP is toxic. As shown in Fig. 2D, these cells have a distinctly different morphology from INS-1E cells. 
Nevertheless, for MJS cells similar results were obtained, i.e. a considerable amount of cell death upon addition 
of hIAPP (Fig. 2E,H), increased viability in the presence of low concentrations of inhibitor (Fig. 2F,H) and no 
apparent cytotoxicity of the inhibitor itself.
Anle145c inhibits hIAPP fibrillation in solution by acting on late oligomers. To gain insight into 
the molecular nature of the interaction between hIAPP and anle145c, we next studied the aggregation behavior of 
hIAPP in the absence and presence of the inhibitor.
The aggregation kinetics of hIAPP were followed using a ThT binding assay. ThT is a widely used fluores-
cent dye that does not bind to monomeric hIAPP, but shows enhanced fluorescence upon binding to amyloid 
structures49. As shown in Fig. 3A, incubation of hIAPP in buffer results in an initial lag phase of ~3 h, followed 
by a steep increase in ThT fluorescence intensity (growth phase), until after ~6 h a saturation level is reached 
(plateau phase). The presence of anle145c already at very low concentrations results in a considerable decrease 
Figure 1. (A) Primary structure of hIAPP. The peptide has a disulfide bond between Cys2 and Cys7 and an 
amidated C-terminus. (B) Chemical structure of the DPP derivative anle145c.
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in fluorescence intensity of the plateau region until at a 1/5 molar ratio of anle145c to hIAPP no fluorescence 
intensity increase can be detected anymore (Fig. 3B). Remarkably, the lag time of fibril formation seems hardly 
affected by the inhibition (Fig. 3C), suggesting that anle145c may act on late oligomers that are present just prior 
to fibril formation, thereby excluding them from participation in the fibrillation process. However, an alternative 
explanation could be that the inhibitor competes with ThT for binding on the fibrils, thereby reducing the ThT 
intensity50.
To discriminate between these possibilities, we performed negative stain TEM. As shown in Fig. 3D, hIAPP 
forms mature amyloid fibrils after 12 hours of incubation, whereas no fibril formation can be observed for hIAPP 
in the presence of anle145c at a 1/5 molar ratio of inhibitor to hIAPP (Fig. 3E). Instead, small non-fibril complexes 
are formed, confirming full inhibition of fibril formation at sub-stoichiometric concentrations of inhibitor.
If the inhibitor indeed acts on late oligomers, it should not significantly affect the kinetics of monomer deple-
tion during aggregation. This was tested by 1H NMR on hIAPP in the absence and presence of anle145c as shown 
in Fig. 3F,G for the aliphatic region. In both cases a reduction of intensity over time is observed, due to depletion 
of monomers during amyloid formation and to the potential depletion of small oligomers that are still sufficiently 
Figure 2. Effect of hIAPP and anle145c on INS-1E and MJS cells. Top: Microscopy images of INS-1E cells 6 h 
after incubation showing (A) untreated cells, (B) cells incubated with 10 µM hIAPP, and (C) cells incubated with 
1 µM anle145c and 10 µM of hIAPP. Middle: Microscopy images of MJS cells 24 h after incubation showing (D) 
untreated cells, (E) cells incubated with 10 µM hIAPP, and (F) cells incubated with 1 µM anle145c and 10 µM 
of hIAPP. The scale bars represent 175 µm. Bottom: Quantification of the percentage of dead cells after 24 h of 
incubation, revealed by DAPI-staining for INS-1E cells (G) and MJS cells (H). Both panels show from left to 
right untreated and DMSO treated cells, followed by 10 µM hIAPP in the presence of different concentrations 
of anle145c, and 5 µM anle145c in the absence of hIAPP as indicated. All samples, except for the untreated cells, 
contained the same final DMSO concentration (5 vol %). The error bars represent the standard error from two 
independent experiments.
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Figure 3. Effect of anle145c on hIAPP fibrillation in solution. (A) Kinetics of hIAPP fibrillation in the absence 
(red) and presence of inhibitor at different anle145c/hIAPP molar ratios as indicated in the figure (B) average 
ThT intensities after 12 hours of incubation and (C) average midpoints (t1/2) of the sigmoidal transition in the 
presence of different concentrations of anle145c. The error bars represent the standard deviation from two 
independent ThT experiments, each carried out in triplicate. (D) Negative stain TEM image of hIAPP after 
12 h incubation in the absence of anle145c and (E) in the presence of anle145c at a 1/5 molar ratio of anle145c 
to hIAPP (white scale bars represent 500 nm). (F) 1H NMR spectra of the aliphatic region of hIAPP in time in 
the absence and (G) in the presence of anle145c at a 1/5 molar ratio of anle145c to hIAPP. The insert shows the 
integrated intensity of the peaks as function of aggregation time, corresponding to depletion of monomers and 
possibly of small, mobile oligomers.
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small and mobile to contribute to the NMR signal51. Quantification of the signal intensity shows that the kinetics 
of monomer and small oligomer depletion indeed are similar with a t1/2 value of 5.7 hours in both cases. The data 
also indicate that hIAPP monomers are consumed almost completely. For the aromatic region no discernable 
signals were left (Supplementary Fig. S1), and hence it can be concluded that at most only a negligible amount of 
hIAPP monomers remain in solution.
Biophysical properties of the anle145c-stabilized oligomeric complexes. The nature of the dif-
ferent hIAPP species formed upon incubation of hIAPP in the absence and presence of anle145c was further 
characterized by different biophysical approaches.
The size of the particles was studied by dynamic light scattering (DLS). Figure 4A shows that freshly dissolved 
monomeric hIAPP in buffer has a hydrodynamic radius (RH) of ~1 nm. After 16 h incubation, only very large 
particles are observed of ~2–10 µm, consistent with the formation of amyloid fibrils. When freshly dissolved 
hIAPP is incubated in the presence of the inhibitor at a sub-stoichiometric ratio of anle145c to hIAPP of 1/5, the 
initial RH is again ~1 nm. However, in this case after incubation only a relatively small increase in RH is observed 
to around 10 nm.
The oligomeric species were further characterized by atomic force microscopy (AFM). As shown in Fig. 4B, 
hIAPP on its own forms fibrils with a length of several µm (left, top), while in the presence of inhibitor only 
small particles are observed (right, top). Individual height profiles obtained by section analysis showed a height 
of ~4–6 nm for the fibrils (left, bottom) and a height of approximately 1–3 nm for the particles in the presence of 
inhibitor.
Finally, the effect of anle145c on the conformational behavior of hIAPP was monitored using CD spectroscopy 
(Fig. 4C). CD spectra of freshly dissolved hIAPP in the absence and presence of anle145c display a peak with neg-
ative ellipticity at 200 nm, indicating that the peptide adopts mostly a random coil structure. After incubation the 
conformation of hIAPP in the absence of inhibitor changes to a pattern with a minimum around 220 nm, indica-
tive of β-sheet formation, whereas no change is observed for hIAPP in the presence of a sub-stoichiometric ratio 
of anle145c to hIAPP of 1/5. These results suggest that anle145c either binds to oligomeric structures in which 
hIAPP has a similar conformation as freshly dissolved hIAPP, or that hIAPP oligomeric structures adopt such a 
conformation upon binding of the inhibitor, thereby effectively preventing it from forming β-sheet like fibrils.
Anle145c converts hIAPP amyloid fibrils into non-toxic oligomeric structures. An important 
question is whether anle145c is able to act on grown fibrils, and, if so, what kind of structures are formed. As 
shown in Fig. 5A, addition of anle145c to hIAPP fibrils, again at a sub-stoichiometric concentration, results in a 
rapid decrease of ThT intensity, suggesting that the hIAPP fibrils undergo remodeling and are converted to smaller 
structures, that do not bind ThT. This was confirmed by EM (Fig. S2). Importantly, DLS measurements (Fig. 5B) 
and AFM measurements (Fig. 5C) show that the particle sizes obtained after starting from fibrils are similar to 
those obtained when the inhibitor is co-incubated with hIAPP monomers (Fig. 4A,B). DLS and AFM measure-
ments in which anle145c was added at different times of incubation (Supplementary Figs. S3 and S4) further 
indicated that the final oligomeric state is independent of the starting aggregation state of hIAPP (Supplementary 
Tables S1 and S2). If this is the case, then anle145c should also be able to convert the β-sheet structures in hIAPP 
fibrils back into a mostly random coil conformation. CD measurements (Fig. 5D) of hIAPP fibrils upon addition 
of anle145c at different incubation times show that the conformation of hIAPP indeed reverts towards the confor-
mation that was observed upon co-incubation of hIAPP monomers with the inhibitor (Fig. 4C).
The anle145c-stabilized oligomers can only be relevant in vivo if they are non-toxic to cells. Thus, the effect of 
the oligomers was tested on INS-1E cell lines. The results, as illustrated in Fig. 5E and quantified in Fig. 5F, show 
that the cells remain mostly viable when they are incubated with anle145c-stabilized oligomers derived from 
incubation of hIAPP fibrils, similar to the situation when monomeric hIAPP is added to cells in the presence of 
anle145c (Fig. 2F,G).
Together, the results obtained from addition of anle145c to hIAPP at different time-points of incubation indi-
cate that anle145c-stabilized oligomers form a thermodynamic sink for the preferred aggregation state of hIAPP 
in the presence of anle145c and that these oligomers are non-cytotoxic.
Discussion
Here we investigated the interaction between the DPP-derived small molecule inhibitor anle145c and hIAPP in 
solution and we investigated the effect of the inhibitor on hIAPP-induced cytotoxicity. We will first discuss the 
situation in solution.
We found that anle145c is a very efficient inhibitor of hIAPP aggregation in solution, with sub-stoichiometric 
concentrations of anle145c being sufficient for full inhibition of fibril formation. Instead of fibrils, oligomeric 
species were formed, which we call “anle145c-stabilized oligomers”. The size distributions as observed by DLS, 
EM and AFM experiments were consistent with oligomers of ~10 nm. The secondary structure of hIAPP in this 
oligomeric complex with anle145c was mostly random coil, similar to that of freshly dissolved monomeric hIAPP, 
but also similar to toxic as well as non-toxic oligomers48.
1H NMR experiments indicated that anle145c does not recruit monomeric hIAPP species or small oligomers, 
since its presence does not seem to affect the half-time of monomer depletion. Moreover, recruitment of mono-
meric species would effectively decrease the hIAPP monomer concentration, leading to an increase in lag-time of 
fibril formation51–53, which was not observed by ThT measurements. Instead, our finding that the lag time for fibril 
formation is independent of the anle145c concentration suggests that anle145c acts on late oligomeric species that 
are present just prior to fibril formation. This would then prevent them from becoming part of the growing fibrils, 
but would not interfere with the process of fibril formation itself.
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It has been proposed that hIAPP oligomers undergo “activation”, i.e. a transition with a high energy bar-
rier, from an oligomer in a random coil organization to an ordered β-sheet oligomer, which then can grow into 
fibrils54. Possibly, anle145c prevents this “activation” step by interacting with oligomeric species and allowing the 
formation of a thermodynamically more favorable state. This state then would consist of anle-stabilized hIAPP 
oligomers, in which hIAPP remains in a mostly random coil conformation.
Figure 4. Characterization of hIAPP aggregates in the absence and presence of anle145c at a 1/5 molar ratio 
of anle145c to hIAPP. (A) DLS results showing the size distribution of hIAPP (left panel) and of hIAPP in the 
presence of anle145c (right panel) at time t = 0 and after 16 h incubation, as indicated in the figure. (B) AFM 
results showing a micrograph (top) and section analysis (bottom) of hIAPP (left panel) and of hIAPP in the 
presence of anle145c (right panel) after 16 h of incubation. (C) CD spectra of hIAPP in solution in the absence 
(blue) and presence (green) of anle145c immediately upon addition (dark lines) and after 22 h of incubation 
(light lines). The spectrum of anle145c in buffer is also shown (black).
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Figure 5. Effects of addition of anle145c to mature hIAPP fibrils at a 1/5 molar ratio of anle145c to hIAPP. 
(A) Kinetics of hIAPP fibril formation in the absence of anle145c (black) and upon addition of anle145c at 
t = 0 (blue) and at t = 8 h (green). (B) DLS showing the size distribution of fully formed hIAPP amyloid fibrils 
before addition of anle145c (top) and 16 h after addition of anle145c (bottom). (C) AFM of hIAPP after 16 h 
incubation, showing fully formed hIAPP fibrils (left) and of the same fibril containing sample after additional 
incubation with anle145c for 23 h (right). (D) CD spectrum of freshly incubated IAPP (dark blue), of hIAPP 
fibrils (light blue) and of hIAPP fibrils upon incubation with anle145c at time points: t = 4 h (light green) 
and t = 16 h (dark green). (E) Microscopy image of INS-1E cell after addition of anle145c-stabilized hIAPP 
oligomers derived by incubation of hIAPP fibrils with anle145c for 16 h (scale 200 μm). (F) Quantification 
of the percentage of dead cells 24 h after addition of hIAPP (left) and 24 h after addition of anle145-stabilized 
oligomers derived from hIAPP fibrils that were incubated with anle145c (right). The error bars represent the 
standard error from two independent experiments.
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Consistent with being the thermodynamically preferred species, anle145c-stabilized oligomers could not only 
be obtained by incubation with monomeric hIAPP species, they also could be derived by incubation with fibrils. 
Both oligomer populations were found to behave very similar, in the sense that they have a similar size distri-
bution and conformation and they are non-toxic to cells. Moreover, addition of anle145c to hIAPP populations 
at different times of incubation suggested that formation of anle145c-stabilized oligomers is controlled by ther-
modynamics, i.e. no matter what the initial population distribution of hIAPP aggregates is, anle145c-stabilized 
oligomers will be obtained with similar final size distributions.
The exact pathways for fibril formation of hIAPP are not known but they are likely to involve many different 
potential oligomeric intermediates48,55,56. In Fig. 6, we present a simplified model to summarize the main effects of 
anle145c on hIAPP in solution. Notably, the stabilization of smaller non-toxic oligomers has also been observed 
in vivo for α-synuclein with the related anle138b40,46. Both observations are consistent with the in vitro design 
principle of the DPP compounds, which is conversion of larger into smaller oligomers40. Nevertheless, the effect 
of anle145c on hIAPP is remarkable for two reasons.
First, we used the more water-soluble variant of the lead compound anle138b, which has not been extensively 
tested so far for its ability to inhibit amyloid formation. Rather surprisingly, the results in this study show that 
anle145c is perhaps the most effective inhibitor for hIAPP fibril formation reported thus far. Indeed, at substoi-
chiometric concentrations of anle145c it was found that (i) fibril formation is prevented, (ii) hIAPP-induced cell 
death is inhibited and (iii) fibrils are converted into non-toxic anle145c-stabilized oligomers. To our knowledge 
this is the first time that such a high efficiency for an hIAPP inhibitor compound is reported for all three effects. 
Anle145c furthermore appears to act in an unprecedented way by trapping hIAPP in a thermodynamic sink in 
the form of non-toxic anle145c-stabilized oligomers.
The second reason why the effects are remarkable, is that a priori one could not have made the assumption that 
DPP compounds would be effective against hIAPP toxic oligomers. This is because hIAPP oligomers have some 
features that are different from those of other well-studied amyloid forming proteins, such as α-synuclein57, i.e. 
they do not exhibit extensive secondary structure and they do not expose hydrophobic surfaces that allow them 
to bind hydrophobic molecules such as 1-anilinonaphtalene-8-sulphonic acid (ANS)48. The efficient inhibition 
of aggregation that was observed in the presence of anle145c, thus highlights the general efficiency of DPP com-
pounds against amyloid aggregation.
In cells, we observed efficient inhibition of the toxic effects of hIAPP at even smaller sub-stoichiometric ratios 
than those required for inhibition of hIAPP aggregation in solution. This is not uncommon, as for inhibitor com-
pounds where comparisons were made, higher as well as lower concentrations were found to be required in cells 
than in solution31,32,58,59. Importantly, the higher efficiency of anle145c in cells further increases the potential of 
this compound as an inhibitor to prevent hIAPP islet amyloid formation and thereby combat T2DM.
In conclusion, this study adds a highly promising inhibitor, anle145c, to the existing array of potential inhib-
itors of hIAPP amyloid formation and it adds T2DM as one more amyloid disease that may be targeted by DPP 
compounds. The results thus highlight the potential of DPP-derived compounds as small molecule oligomer 
modulators for amyloid diseases in general.
Experimental Procedures
Materials. Human hIAPP (amino acid sequence: KCNTATCATQRLANFLVHSSNNFGAILSSTNVGSNTY 
including disulfide bond and amidated C-terminus) was obtained from Bachem AG (batch number 7001439). 
Thioflavin T (ThT) was obtained from Sigma Aldrich. Anle145c was supplied by the NMR-based structural biol-
ogy department, (MPIbpc, Göttingen, Germany) and was synthesized as described previously40.
Figure 6. Model for the interaction of anle145c with hIAPP. Thermodynamics are qualitatively represented 
by the horizontal bars under the different aggregate states as differences in ΔG and kinetics are represented 
by arrows. The aggregation state is qualitatively represented on the horizontal axis. In the absence of anle145c 
(black arrows), hIAPP molecules in random coil conformation (1) interact with each other to form oligomers 
(2). In time the nature of these oligomers changes and β-sheet structures will be formed (3) that eventually 
will grow into mature amyloid fibrils (4) which are considered to be the thermodynamically most stable form. 
When hIAPP is incubated in the presence of anle145c (red arrows) it interacts with (late) hIAPP oligomers 
to form stable, non-toxic anle145c-stabilized oligomers (5), where the oligomers retain a mostly random coil 
configuration. Similar non-toxic anle145c-stabilized oligomers are obtained when anle145c is added to grown 
fibrils or to hIAPP aggregates formed at other time points, indicating that the anle145c-stabilized oligomers act 
as a thermodynamic sink. The exact pathway by which these anle145c-stabilized oligomers are formed is not 
known.
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Preparation of stock solutions of hIAPP. hIAPP stock solutions were prepared as described previously60. 
Briefly, hIAPP was dissolved in 1, 1, 1, 3, 3, 3-hexafluoro-2-propanol (HFIP) and incubated for 1 hour to eliminate 
any pre-existing supramolecular structures. HFIP was evaporated using nitrogen gas followed by 1 h in a vacuum 
desiccator. For the fluorescence, microscopy (TEM, AFM), DLS and cell viability assays, the resulting peptide film 
was dissolved in DMSO at 2 mM and incubated for one hour. If required, hIAPP was further diluted in DMSO 
to the desired concentration. For the NMR experiments, the peptide film was solubilized at a concentration of 
50 µM in 10 mM phosphate buffer, pH 7.4 in D2O. For the CD experiments, the peptide film was solubilized at a 
concentration of 25 µM in 10 mM phosphate buffer, pH 7.4.
Preparation of stock solutions of anle145c. Stock solutions of anle145c were prepared as 10 mM solu-
tions in DMSO, or in DMSO-d6 for the NMR experiments.
ThT fluorescence assay. Thioflavin-T binding fluorescence assays were performed using a Spectrafluor 
Tecan (Salzburg, Austria) plate reader as previously described61. The kinetics of fibril formation were measured by 
monitoring the fluorescence intensity increase upon binding of the fluorescent dye Thioflavin T (ThT) to fibrils. 
A plate reader and standard 96-wells flat-bottom black microtiter plates in combination with a 430 nm excitation 
filter and a 535 nm emission filter were used. First 2.5 µL of an anle145c solution in DMSO at the desired con-
centration was added to 195 µL of a buffer containing 10 µM of ThT, 10 mM Tris-HCl, 100 mM NaCl at pH 7.4. 
The ThT assay was then started by adding 2.5 µL of a 0.4 mM hIAPP solution in DMSO. The microtiter plate was 
shaken for 10 s directly after addition of all components, but not during the measurement. All ThT assays were 
performed on triplicate samples on different days and using different hIAPP stock solutions. The resulting curves 
were analyzed using ORIGIN program and fitted to a Boltzmann sigmoidal equation, where Fi and Ft are the 
initial and final fluorescence values. This fitting allows the estimation of kinetic parameters such as the time for 









Transmission electron microscopy. TEM images were recorded using a Technai 12 electron microscope 
operating at 120 kV as previously described61. hIAPP in solution was incubated in the absence and presence of 
anle145c under the same conditions as in the Thioflavin T assay. Aliquots (20 μL) of this mixture were placed onto 
glow-discharged 300-mesh carbon-coated copper grids for 2 min, then the grids were blotted and dried. Grids 
were negatively-stained, as described previously61, with saturated uranyl acetate (2% w/v) for 45 s, after which 
they were blotted and dried. Grids were examined using a Technai 12 electron microscope operating at 120 kV.
cell cultures. INS-1E rat insulinoma cells were cultured in RPMI 16% FCS, 100 U/ml penicillin, 100 µg/
ml streptomycin, 10 mM HEPES, 1 mM sodium pyruvate, 2.5 mM glucose and 50 µM β-mercapto-ethanol. The 
human melanoma cell line MelJuSo (MJS) was cultured in RPMI 1640 (Invitrogen) containing 10% FCS (PAA 
laboratories), 100 U/ml penicillin, 100 µg/ml streptomycin and 2 mM L-glutamine (complete medium). All cell 
lines were cultivated at 37 °C and 5% CO2.
Flow cytometry based DAPI staining. Cells were seeded prior to incubation with hIAPP. hIAPP was 
added to the cells in the presence of varying concentrations of anle145c. The final concentration of hIAPP was 
10 µM. After treatment the cells were thoroughly washed with PBS, trypsinized and transferred to 96-well plates. 
The cells were incubated for 10 min with DAPI (2 µg/ml) and washed three times to remove the staining solution. 
All samples were measured by flow cytometry using a FACS Canto II and analyzed using FlowJo V10 software.
NMR spectroscopy. NMR experiments were recorded on a Bruker Avance III spectrometer operating at 
a 1H frequency of 500 MHz and equipped with a TCI cryoprobe (temperature 20 °C) as previously described51. 
Experiments were processed and analyzed with TopSpin program (Bruker). Measurements were carried out in 
10 mM potassium phosphate buffer in D2O at pH 7.4. Peptide concentrations were 50 µM in the absence and in 
the presence of anle145c. The peptide film was dissolved in the phosphate buffer and immediately transferred in 
a Shigemi tube of 5 mm diameter, comprising a sample volume of 300 µL. The evolution in time of the peptide 
signal intensity was followed by recording one-dimensional 1H spectra until the peptide signal intensity decayed 
completely. Peptide 1H resonances (both in the aliphatic and in the amide/aromatic region) were then integrated 
and these values are plotted as a function of time, leading to a sigmoidal curve that can be fitted using R program 
by a Boltzmann sigmoidal equation.
DLS analysis. DLS measurements of hIAPP in the absence and presence of varying concentrations of 
anle145c were performed at room temperature on a Zetasizer Nano ZS (Malvern Instruments, United Kingdom). 
Aliquots of 2.5 µL of an anle145c solution in DMSO at the desired concentration were added to 195 µL of a buffer 
containing 10 mM Tris-HCl, 100 mM NaCl at pH 7.4. Subsequently 2.5 µL of a 0.4 mM hIAPP solution in DMSO 
was added and the mixture was transferred to a low volume cuvette for measurements. Each measurement was 
an average of seven runs and took about 7 minutes to complete. The volume percentage was recorded, which 
describes the relative proportion of multiple components in the sample based on their mass or volume rather 
than based on their scattering (intensity). Processing of the data was automated through the Zetasizer software.
AFM analysis. AFM measurements were performed at room temperature using scan rates between 1.0 and 
1.5 Hz in the tapping mode on a MultiMode scanning probe microscope equipped with a Nano-Scope IIIa con-
troller (Digital Instruments) using an E-scanner (scan size 15 mm-615 mm) and a MMMC cantilever holder 
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(Veeco Instruments, Mannheim, Germany) equipped with a silicon SPM sensor (PPPNCHR, NanoAndMore, 
Wetzlar, Germany) as previously described62. hIAPP (50 µM) without and with anle145c (10 µM) was incubated 
for various time intervals in 10 mM Tris-HCl, 150 mM NaCl buffer solution and then deposited on freshly cleaved 
mica. The samples were dried with a gentle stream of nitrogen, rinsed with water, dried again with a stream of 
nitrogen and finally freeze-dried overnight, as described previously61. The dried samples were scanned in air with 
drive frequencies around 240 kHz and drive amplitudes between 15 and 379 mV. All height and amplitude images 
of sample regions were acquired with resolution of 5.1 Mpixels. For image analysis and processing, the software 
NanoScope version 5 (Veeco Instruments, Mannheim, Germany) was used.
CD spectroscopy. CD spectra were measured on a Jasco 810 spectropolarimeter (Jasco Inc., Easton, MD). 
Measurements were carried out in cells of 0.1 cm path length at room temperature in 10 mM phosphate buffer at 
pH 7.4 of hIAPP at different times of incubation in the presence and absence of anle145c. Measurements were 
taken every 0.2 nm at a scan rate of 20 nm/min. Each spectrum reported is the average of five scans. The peptide 
concentration was 25 µM. anle145c was added at a 5/1 molar ratio of hIAPP to anle145c61.
Abbreviations. hIAPP, human islet amyloid polypeptide; ThT, thioflavin; RH, hydrodynamic radius; DLS, 
dynamic light scattering; AFM, atomic force microscopy; EM, electron microscopy. T2DM, type 2 diabetes; DPP, 
diphenylpyrazole.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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